Overview

Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

Status:
Terminated
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This is a study to be performed in Qatar that will look at the comparison of glycemic control in patients with type 2 diabetes on insulin glargine U100 with insulin degludec over the Ramadan period, to determine whether better glycemic control with fewer hypoglycemic episodes can be achieved.
Phase:
Phase 4
Details
Lead Sponsor:
Weill Cornell Medical College in Qatar
Collaborator:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc
Insulin, Long-Acting